Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
EEG-Based Brain-Computer Interface Project for Individuals With ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular condition characterized
by weakness, muscle wasting, fasciculations and increased reflexes. Depending on the site of
onset, individuals with ALS progressively lose control of their skeletal muscles; bulbar or
the extremities. As symptoms worsen and spread, muscle atrophy becomes apparent and upper
motor neuron symptoms such as spasticity complicate gait (in lower limb involvement) and
manual dexterity (in upper limb involvement). The patients progress to a state of profound
disability and have great difficulty in communicating; some may even be entirely "locked in"
to their bodies. The capacity for simple communication could greatly improve their quality
of life.
New technologies are giving people with disabilities alternate communication and control
options. One such instrument is the EEG-based Brain-Computer Interface (BCI) which can
provide both communication and control functions to those who have lost muscle control. By
recording electroencephalographic (EEG) signals or brain waves from the scalp and then
decoding them, the Wadsworth BCI allows people to make selections on a computer screen [i]
In this study we will be investigating the feasibility of using EEG-based Brain-Computer
Interface technology as a communication solution for individuals with ALS. The specific
question addressed will be: Can individuals with ALS use the BCI for communication when they
present with extreme loss of neuromuscular control and severe communication impairments? The
goal of the project is to determine whether this device is a practical and realistic means
for individuals with ALS to communicate. The study is intended to evaluate both the
complexity of the system and the degree to which each participant will be able to
communicate. Trials will consist of asking the subject to follow a series of simple
instructions and complete certain tasks while using the BCI.
This study design requires that the individual live in the Philadelphia region. Please
contact the Wadsworth Center of the New York State Department of Health and State University
of New York at Albany directly if you reside outside of this area.
This study design requires that the individual live in the Philadelphia region. Please contact the Wadsworth Center of the New York State Department of Health and State University of New York at Albany directly if you reside outside of this area. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
| Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
| Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
| Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
| Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
| Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
| Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
| Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
| Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
| Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
| Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
| Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
| Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |